Participated in Prevision Medicine's $5.4M seed round led by ACE Ventures.
SEP 24, 2026
Swiss precision oncology company offering personalized ex vivo drug-screening tests
Swiss precision oncology company offering personalized ex vivo drug-screening tests. Its proprietary PrevisionOne platform tests living cancer and healthy cells from patient biopsies against cancer drugs and combinations, then ranks therapies by selective cancer-cell killing and provides an actionable report to support oncologists’ treatment decisions. Tests cover hematologic cancers and solid tumors, with reported turnaround times of about 72 hours to five days.